Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1802 1
1840 2
1841 4
1842 2
1855 1
1865 1
1867 1
1923 1
1927 1
1928 3
1929 1
1930 2
1931 1
1932 2
1936 1
1941 1
1945 31
1946 49
1947 62
1948 36
1949 83
1950 18
1951 12
1952 16
1953 14
1954 14
1955 18
1956 19
1957 40
1958 28
1959 37
1960 34
1961 40
1962 38
1963 33
1964 43
1965 48
1966 40
1967 34
1968 36
1969 39
1970 36
1971 49
1972 45
1973 33
1974 45
1975 63
1976 99
1977 88
1978 88
1979 134
1980 93
1981 103
1982 105
1983 134
1984 120
1985 141
1986 128
1987 173
1988 168
1989 193
1990 197
1991 188
1992 232
1993 223
1994 221
1995 217
1996 265
1997 274
1998 275
1999 295
2000 324
2001 302
2002 323
2003 337
2004 345
2005 407
2006 403
2007 446
2008 483
2009 524
2010 555
2011 581
2012 642
2013 697
2014 728
2015 791
2016 725
2017 705
2018 808
2019 820
2020 1053
2021 1167
2022 1040
2023 984
2024 899
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,636 results

Results by year

Filters applied: . Clear all
Page 1
Bacille Calmette-Guerin: An ophthalmic perspective.
Jain M, Vadboncoeur J, Garg SJ, Biswas J. Jain M, et al. Surv Ophthalmol. 2022 Mar-Apr;67(2):307-320. doi: 10.1016/j.survophthal.2021.07.005. Epub 2021 Jul 31. Surv Ophthalmol. 2022. PMID: 34343536 Free PMC article. Review.
Vaccines such as bacille Calmette-Guerin (BCG) are known for their heterologous effects mediated through a number of mechanisms, including trained immunity constituted by monocyte-macrophage based innate immunity. ...
Vaccines such as bacille Calmette-Guerin (BCG) are known for their heterologous effects mediated through a number of mechanisms, incl …
Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
Kikuchi E, Hayakawa N, Fukumoto K, Shigeta K, Matsumoto K. Kikuchi E, et al. Int J Urol. 2020 Feb;27(2):108-116. doi: 10.1111/iju.14153. Epub 2019 Dec 3. Int J Urol. 2020. PMID: 31793703 Review.
Bacillus Calmette-Guerin induction with or without maintenance is the gold standard therapy for intermediate-/high-risk non-muscle-invasive bladder cancer; however, one-third of patients treated with adequate bacillus Calmette-Guerin therapy do not achieve sufficien …
Bacillus Calmette-Guerin induction with or without maintenance is the gold standard therapy for intermediate-/high-risk non-muscle-in …
Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J, Onozawa M, Takaoka E, Yano I. Miyazaki J, et al. Int J Urol. 2018 May;25(5):405-413. doi: 10.1111/iju.13538. Epub 2018 Mar 5. Int J Urol. 2018. PMID: 29506322 Review.
There are thus ongoing research efforts to assess the effects of these genetic alterations on the properties of bacillus Calmette-Guerin strains, with the ultimate goal of identifying an ideal bacillus Calmette-Guerin strain for treatment of non-muscle-invasive blad …
There are thus ongoing research efforts to assess the effects of these genetic alterations on the properties of bacillus Calmette-Guerin …
Bacille-Calmette-Guerin non-responders: how to manage.
von Rundstedt FC, Lerner SP. von Rundstedt FC, et al. Transl Androl Urol. 2015 Jun;4(3):244-53. doi: 10.3978/j.issn.2223-4683.2015.05.03. Transl Androl Urol. 2015. PMID: 26816828 Free PMC article. Review.
Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). ...
Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-mu …
Intravesical bacillus Calmette-Guerin for bladder cancer: are all the strains equal?
D'Andrea D, Gontero P, Shariat SF, Soria F. D'Andrea D, et al. Transl Androl Urol. 2019 Feb;8(1):85-93. doi: 10.21037/tau.2018.08.19. Transl Androl Urol. 2019. PMID: 30976572 Free PMC article. Review.
Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is the standard of care for high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). ...
Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is the standard of care for high-risk and intermediate-risk non-muscle …
Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review.
Saluja M, Gilling P. Saluja M, et al. Int J Urol. 2018 Jan;25(1):18-24. doi: 10.1111/iju.13410. Epub 2017 Jul 25. Int J Urol. 2018. PMID: 28741703 Review.
Intravesical bacillus Calmette-Guerin has been the standard of care for high-risk non-muscle-invasive bladder cancer for 40 years. ...The present review provides insights into the role of bacillus Calmette-Guerin compared with alternative treatments both in primary …
Intravesical bacillus Calmette-Guerin has been the standard of care for high-risk non-muscle-invasive bladder cancer for 40 years. .. …
Emerging Immunotherapy Options for bacillus Calmette-Guerin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC. Meng MV, et al. J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1. J Urol. 2019. PMID: 31042108 Review.
This is particularly true for patients with recurrence after optimal intravesical bacillus Calmette-Guerin therapy, who are classified as having bacillus Calmette-Guerin unresponsive disease. ...CONCLUSIONS: There is a clear biological and clinical rationale for the …
This is particularly true for patients with recurrence after optimal intravesical bacillus Calmette-Guerin therapy, who are classifie …
Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer.
Wang Z, So WZ, Loh KY, Lim YK, Mahendran R, Wu QH, Chiong E. Wang Z, et al. Int J Urol. 2022 Aug;29(8):807-815. doi: 10.1111/iju.14921. Epub 2022 May 22. Int J Urol. 2022. PMID: 35598896 Free PMC article. Review.
Within the heterogeneous population of patients with bacillus Calmette-Guerin failure, there are clear differences in prognosis and therapy with regard to the timeline when bacillus Calmette-Guerin failure occurred. ...We hereby summarize the different biomarkers th …
Within the heterogeneous population of patients with bacillus Calmette-Guerin failure, there are clear differences in prognosis and t …
A systematic review on the available treatment modalities for Bacillus Calmette-Guerin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.
Syed S, Rahman M, Israr A, Anwar M, Khatroth S, Safi D, Kamran A. Syed S, et al. SAGE Open Med. 2023 Mar 16;11:20503121231160408. doi: 10.1177/20503121231160408. eCollection 2023. SAGE Open Med. 2023. PMID: 36949824 Free PMC article. Review.
The optimal management of patients with Bacillus Calmette-Guerin-unresponsive disease remains to be a challenge. The purpose of this study was to conduct a systematic review on the treatment modalities available for the management of Bacillus Calmette-Guerin-unrespo …
The optimal management of patients with Bacillus Calmette-Guerin-unresponsive disease remains to be a challenge. The purpose of this …
Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guerin Failure.
Becker REN, Kates MR, Bivalacqua TJ. Becker REN, et al. Urol Clin North Am. 2020 Feb;47(1):15-21. doi: 10.1016/j.ucl.2019.09.004. Urol Clin North Am. 2020. PMID: 31757296 Review.
Disease progression and recurrence are common among patients on Bacillus Calmette-Guerin (BCG) therapy, and options for bladder-preserving subsequent therapy remain limited. ...
Disease progression and recurrence are common among patients on Bacillus Calmette-Guerin (BCG) therapy, and options for bladder-prese …
19,636 results
You have reached the last available page of results. Please see the User Guide for more information.